Treatment of clinically isolated syndrome with low dose naltrexone

Condition:

Category: General

Author: M. Ludwig

Type: Article

Date: 2015

The purpose of this study was to evaluate CIS patients prescribed low dose naltrexone (LDN), an inexpensive, safe and tolerable compound that triggers endogenous enkephalin/endorphin release by the patient. Patients reported that LDN therapy was without side effect and stabilized or improved their perceived quality of life and clinical status, including the reduction of fatigue.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Not Finding What You're Looking For?

Fill out the form below to let us know.

>